

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568 **E-mail:** bpgoffice@wjgnet.com https://www.wjgnet.com

PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Cases

Manuscript NO: 75818

Title: Primary squamous cell carcinoma of the liver: A case report

Provenance and peer review: Unsolicited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 02719046

Position: Peer Reviewer

Academic degree: PhD

Professional title: Associate Professor

Reviewer's Country/Territory: Tunisia

Author's Country/Territory: China

Manuscript submission date: 2022-02-16

Reviewer chosen by: AI Technique

Reviewer accepted review: 2022-02-16 15:41

Reviewer performed review: 2022-02-18 16:28

Review time: 2 Days

Scientific quality	[] Grade A: Excellent [] Grade B: Very good [] Grade C: Good [Y] Grade D: Fair [] Grade E: Do not publish
Language quality	 [] Grade A: Priority publishing [Y] Grade B: Minor language polishing [] Grade C: A great deal of language polishing [] Grade D: Rejection
Conclusion	 [] Accept (High priority) [] Accept (General priority) [] Minor revision [Y] Major revision [] Rejection
Re-review	[]Yes [Y]No
Peer-reviewer	Peer-Review: [Y] Anonymous [] Onymous



Baishideng **Publishing**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568 E-mail: bpgoffice@wjgnet.com https://www.wjgnet.com

statements

Conflicts-of-Interest: [] Yes [Y] No

SPECIFIC COMMENTS TO AUTHORS

The authors should describe the histology of hepatic squamous cell carcinoma in the clincal history The quality of histological figures is poor. Thus, they must be replaced. The authors should add a figure illustrating the gross features of the hepatic tumor. Chest X-ray as well as thoracic CT scan must be performed in order to exclude a pulmonary origin of the hepatic squamous cell carcinoma. Squamous cell carcinoma of the lung is negative for TTF1. Colonoscopy should be performed so as to exclude a colorecal or anal tumor



7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568 **E-mail:** bpgoffice@wjgnet.com https://www.wjgnet.com

PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Cases

Manuscript NO: 75818

Title: Primary squamous cell carcinoma of the liver: A case report

Provenance and peer review: Unsolicited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 02510220

Position: Editor-in-Chief

Academic degree: MD

Professional title: Academic Research, Full Professor

Reviewer's Country/Territory: Poland

Author's Country/Territory: China

Manuscript submission date: 2022-02-16

Reviewer chosen by: AI Technique

Reviewer accepted review: 2022-02-19 15:12

Reviewer performed review: 2022-02-19 15:39

Review time: 1 Hour

Scientific quality	[] Grade A: Excellent [] Grade B: Very good [] Grade C: Good [Y] Grade D: Fair [] Grade E: Do not publish
Language quality	[] Grade A: Priority publishing [] Grade B: Minor language polishing [Y] Grade C: A great deal of language polishing [] Grade D: Rejection
Conclusion	 [] Accept (High priority) [] Accept (General priority) [] Minor revision [Y] Major revision [] Rejection
Re-review	[Y]Yes []No
Peer-reviewer	Peer-Review: [Y] Anonymous [] Onymous



Baishideng **Publishing**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA Telephone: +1-925-399-1568 E-mail: bpgoffice@wjgnet.com https://www.wjgnet.com

statements

Conflicts-of-Interest: [] Yes [Y] No

SPECIFIC COMMENTS TO AUTHORS

The authors present a rare case of liver cancer with squamous histology. There is no novelty. The description is correct, but the authors present too much laboratory data that are not informative. The authors do not present any data showing that the case was special. The study should present a table with all already published cases and the outcome. The reader will expect to gen a complete knowledge of what to do with such a rare case. The risk of progression, the effectiveness of RTH, and CTH. A longer one-year follow-up would be nice. In addition: 1. It is unclear what kind of CTH after surgery was offered and why? 2. What kind of antibodies in immunotherapy were used? 3. What it means "poor findings for the esophagus" 4. Please explain the set of immunochemistry used.